Javascript must be enabled to continue!
Micellar‐based spectrofluorimetric method for the selective determination of ledipasvir in the presence of sofosbuvir: application to dosage forms and human plasma
View through CrossRef
AbstractA fast, low‐cost, sensitive, and selective spectrofluorimetric method for the determination of ledipasvir was developed and validated. The method is based on an enhancement in the native fluorescence intensity of ledipasvir by 500% of its original value by the formation of hydrogen bonds between the cited drug and Tween‐20 in the micellar system (pH = 5.0). All fluorescence measurements were carried out at 425 nm and 340 nm for emission and excitation wavelengths, respectively. A linear relationship between the concentration of ledipasvir and the observed fluorescence intensity was achieved in the range of 0.1–2.0 μg ml−1 with 0.028, 0.084 μg ml−1, for detection and quantitation limits, respectively. The acquired selectivity and sensitivity using the proposed method facilitate the analysis of ledipasvir in spiked human plasma with sufficient percentage recovery (95.36–99.30%). The proposed method was developed and validated according to International Council for Harmonisation (ICH) guidelines. Moreover, the cited drug was successfully determined in its pharmaceutical dosage form using the proposed method. In addition, the validity of the proposed results was statistically confirmed using Student's t‐test, variance ratio F‐test, and interval hypothesis test.
Title: Micellar‐based spectrofluorimetric method for the selective determination of ledipasvir in the presence of sofosbuvir: application to dosage forms and human plasma
Description:
AbstractA fast, low‐cost, sensitive, and selective spectrofluorimetric method for the determination of ledipasvir was developed and validated.
The method is based on an enhancement in the native fluorescence intensity of ledipasvir by 500% of its original value by the formation of hydrogen bonds between the cited drug and Tween‐20 in the micellar system (pH = 5.
0).
All fluorescence measurements were carried out at 425 nm and 340 nm for emission and excitation wavelengths, respectively.
A linear relationship between the concentration of ledipasvir and the observed fluorescence intensity was achieved in the range of 0.
1–2.
0 μg ml−1 with 0.
028, 0.
084 μg ml−1, for detection and quantitation limits, respectively.
The acquired selectivity and sensitivity using the proposed method facilitate the analysis of ledipasvir in spiked human plasma with sufficient percentage recovery (95.
36–99.
30%).
The proposed method was developed and validated according to International Council for Harmonisation (ICH) guidelines.
Moreover, the cited drug was successfully determined in its pharmaceutical dosage form using the proposed method.
In addition, the validity of the proposed results was statistically confirmed using Student's t‐test, variance ratio F‐test, and interval hypothesis test.
Related Results
Simultaneous estimation of ledipasvir and sofosbuvir in bulk and its dosage forms by stability indicating RP-HPLC method
Simultaneous estimation of ledipasvir and sofosbuvir in bulk and its dosage forms by stability indicating RP-HPLC method
The fixed-dose ledipasvir-sofosbuvir combination offers an effective and well-tolerated pill for the treatment of chronic hepatitis C infection. Only a few analytical works were ca...
Innovative Thin-Layer Chromatography/Fluorescence Detection Approach for Sensitive and Specific Determination of Ledipasvir in Rats’ Feces and Pharmaceutical Dosage Form
Innovative Thin-Layer Chromatography/Fluorescence Detection Approach for Sensitive and Specific Determination of Ledipasvir in Rats’ Feces and Pharmaceutical Dosage Form
Abstract
An innovative thin-layer chromatography method coupled with the fluorescence detection was developed for a specific estimation of ledipasvir. The separation...
Safety and Efficacy of Sofosbuvir plus Ledipasvir with and without Ribavirin for Chronic HCV Genotype-1 Infection: A Systematic Review and Meta-Analysis
Safety and Efficacy of Sofosbuvir plus Ledipasvir with and without Ribavirin for Chronic HCV Genotype-1 Infection: A Systematic Review and Meta-Analysis
Background
Ledipasvir and sofosbuvir are new direct-acting antiviral agents for patients with HCV infection. Ledipasvir inhibits the HCV non-structural 5A prote...
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial
COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is an approved d...
Well Injection Tests Of Non-Newtonian Fluids
Well Injection Tests Of Non-Newtonian Fluids
Abstract
In this study, the flow behavior of polymer solutions and micellar solutions in the reservoir was analyzed using the steady state radial flow test (Hall ...
Micellar Solution Flooding - Field Test Results And Process Improvements
Micellar Solution Flooding - Field Test Results And Process Improvements
Abstract
Up-to-date results of large and small micellar solution field tests illustrate the successful application of the process. Advances in techniques for labo...
Chemical Movement in Micellar Flooding: Determination of Sulfonates and Polymers by Liquid Chromatography
Chemical Movement in Micellar Flooding: Determination of Sulfonates and Polymers by Liquid Chromatography
American Institute of Mining, Metallurgical, and Petroleum Engineers, Inc.
Abstract
Now liquid chromatographic procedures, colum...
"TREATMENT SUCCESS OF SOFOSBUVIR AND DACLATSVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS OFHEPATITIS C VIRUS"
"TREATMENT SUCCESS OF SOFOSBUVIR AND DACLATSVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS OFHEPATITIS C VIRUS"
Background:To compare the frequency of responders achieving SVR12 after taking sofosbuvir and daclatasvir with vs without ribavirin.Material and Methods:Total 180 patients meeting ...

